J & J Vision inks $26m Singapore collaborative myopia research deal

Johnson & Johnson‘s (NYSE:JNJ) Vision business said this week that it inked an approximately $26.4 million collaborative research deal with The Singapore National Eye Centre and the Singapore Eye Research Institute looking to improve treatments for myopia. The public-private strategic partnership is the first of its kind in Asia, according J&J, and will promote exploration of how myopia develops, progresses and possible interventions. “SNEC is honored to be working with collaborators coming together to address the growing burden of myopia,” Professor Wong said. “By leveraging the diverse strengths of our clinicians, clinician scientists and strategic partners to establish new disease frameworks and share this knowledge across world communities to help eradicate myopia,” SNEC medical director Wong Tien Yin said in a prepared statement. “The incidence of myopia is increasing at an alarming rate around the world and if left unchecked, the human and financial toll could skyrocket in the coming decades, especially in Asia. We are delighted to be collaborating with SERI and SNEC to better understand the underpinnings of this condition and identify ways to halt this global public health threat. Together, we hope to bring important progress to individuals and families throughout the Asia Pacific region and ultimately, around the world,” J&J chief scientific officer Dr. Paul Stoffels said in a prepared release. The groups will ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Optical/Ophthalmic Research & Development johnsonandjohnson Source Type: news